Mergers & Acquisitions ·
Galera Therapeutics completed its merger with Obsidian Therapeutics on August 3, 2026, becoming a wholly owned…
GRTXDGalera Therapeutics, Inc.
Galera Therapeutics completed its merger with Obsidian Therapeutics on August 3, 2026, becoming a wholly owned subsidiary of the combined entity. Galera shareholders received an exchange ratio of 0.7019 shares of Parent Common Stock for each share held and were issued one Contingent Value Right (CVR) per share. These CVRs entitle holders to 80% of net proceeds from Legacy Product commercialization over five years and 95% from the Supportive-Care Product Divestiture over ten years. Galera Common Stock ceased trading on the OTCQB Market, and the company intends to file Form 15 to terminate its SEC reporting obligations. Executive leadership transitioned immediately upon closing, with J. Mel Sorensen resigning as President and CEO while new officers were appointed for the surviving subsidiary. Galera Therapeutics operates in the biotechnology industry, focusing on developing therapies for rare diseases.